China adds 107 drugs to insurance list; Europe backs lung cancer treatments; FDA decision pending for ivonescimab
Summary
Speakers report that China's National Healthcare Security Administration added 107 new drugs to its 2026 National Reimbursement Drug List, including a record 51 Class 1 innovative drugs. JW Therapeutics' CAR-T therapy and Novo Nordisk's insulin-semaglutide combination were highlighted as notable additions. In Europe, the EMA's CHMP backed Hansoh's aumolertinib and Innovent's sintilimab for lung cancer. Meanwhile, the FDA's decision on Akeso's ivonescimab remained pending as of the episode's recording. The speakers also discussed US regulatory restrictions on genetic data exports and their impact on clinical trials.
Key takeaways
- 1 China's 2026 National Reimbursement Drug List added 107 drugs, with 51 being Class 1 innovative drugs, marking a record number of new medicines entering the state basic medical insurance fund.
Ning · 0:47
- 2 GLP-1 drugs added to China's list, including Innovent's mazdutide, are reimbursed only for diabetes treatment, excluding weight loss indications, despite the drugs' appetite-suppressing properties.
Ning · 3:08
- 3 Novo says that makes China the first country anywhere to reimburse it. A Danish company's new weekly diabetes shot, and the first country to reimburse it is China.
Basil Lui · 3:42
- 4 The FDA's target date for ivonescimab is November 14, but as of 6:00 AM Singapore time on that Saturday, the decision remained pending, with Summit Therapeutics' latest SEC filing dated November 4.
Ning · 5:34
Episode sections
- 0:04 – 0:47
Intro and AI-voice disclosure
Basil Lui introduces the show and the topic of China adding 107 drugs to its national insurance list. Ning clarifies that both voices are AI clones, but Basil Lui is the real person behind the show, and states that personal views are not investment advice.
- 0:47 – 2:51
China's 2026 drug list: 107 new drugs
Ning reports that China's National Healthcare Security Administration published the 2026 National Reimbursement Drug List in Suzhou, adding 107 drugs, 51 of which are Class 1 innovative drugs, a record number. Basil Lui identifies JW Therapeutics' relma-cel as the first CAR-T on the basic list, priced at 1.29 million yuan per dose, moving from a commercial list to the basic state list.
- 2:51 – 5:34
GLP-1s, Novo and iza-bren
Ning notes that four GLP-1 injections, including Innovent's mazdutide, were added but reimbursed only for diabetes, not weight loss. Basil Lui highlights that Novo Nordisk's nohoje (insulin-semaglutide combination) was added for type 2 diabetes, making China the first country to reimburse it. Ning adds that Biokin's iza-bren was added for nasopharyngeal cancer.
- 5:34 – 6:23
Ivonescimab: no FD
Ning states that the FDA target date for ivonescimab is November 14, but as of 6:00 AM Singapore time on Saturday, the decision was still pending. Basil Lui clarifies that a target date is not a legal deadline and silence does not indicate the outcome. He also notes reports of commercial leadership departures at Summit Therapeutics.
- 6:23 – 9:43
European approvals and regulatory context
Ning reports that the European Medicines Agency's CHMP backed Hansoh's aumolertinib and Innovent's sintilimab for lung cancer. Basil Lui explains the complex history of aumolertinib's approval and revocation involving AstraZeneca. He contrasts China's volume-for-price model with US price reference policies and discusses new Chinese rules on exporting human genetic resources.
- 9:43 – 11:08
US restrictions and lab infrastructure
Basil Lui outlines US rules barring Americans from providing China with bulk genetic data and mentions the upcoming White House list of biotechnology companies of concern. He cites LabCorp's claims about its Shanghai and Singapore labs, noting Singapore as a neutral option for Asia Pacific trials, though no public evidence exists of Chinese samples going to Singapore labs.
- 11:08 – 12:08
Conclusion and next steps
Ning summarizes that Beijing renewed ivonescimab and added 107 drugs, Europe backed two Chinese lung cancer drugs, and Washington has not yet decided on ivonescimab. Basil Lui announces the next episode will discuss patient origins and FDA decisions, and directs listeners to follow the show on Spotify or Apple Podcasts.
Claims worth verifying
China's National Healthcare Security Administration published the 2026 National Reimbursement Drug List in Suzhou on Saturday, adding 107 drugs, 51 of which are Class 1 innovative drugs.
Unidentified speaker (UNKNOWN) ·0:47
How to verify: Check the official announcement on the National Healthcare Security Administration (NHSA) website or Chinese state media reports from November 2026. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
JW Therapeutics' relma-cel (Kiteva) is the first CAR-T therapy on China's basic insurance list, priced at 1.29 million yuan per dose.
Basil Lui ·1:33
How to verify: Check the 2026 National Reimbursement Drug List published by NHSA and JW Therapeutics' investor relations announcements or press releases regarding the drug's pricing and inclusion. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
Relma-cel was previously on a separate commercial health insurer list before moving to the basic state list in 2026.
Ning ·1:57
How to verify: Review NHSA announcements regarding the commercial drug list and the transition of drugs to the basic insurance list. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
Innovent's mazdutide was added to China's reimbursement list but reimbursed only for diabetes, not weight loss.
Ning ·2:51
How to verify: Check the NHSA's 2026 reimbursement list details and Innovent's investor presentations or press releases regarding the approved indications. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
Novo Nordisk's nohoje (insulin-semaglutide combination) was added to China's reimbursement list for type 2 diabetes, making China the first country to reimburse it.
Basil Lui ·3:22
How to verify: Check Novo Nordisk's press releases or investor presentations confirming China as the first market for nohoje reimbursement, and NHSA's 2026 list. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
Biokin's iza-bren was added to China's reimbursement list for nasopharyngeal cancer.
Ning ·3:53
How to verify: Check Biokin's investor relations announcements or press releases regarding the drug's inclusion in the 2026 reimbursement list. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
Akeso's ivonescimab was renewed at its original price in China's reimbursement list.
Basil Lui ·4:17
How to verify: Check Akeso's investor presentations or press releases confirming the renewal terms of ivonescimab in the 2026 list. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
The FDA's target date for ivonescimab is November 14, but as of 6:00 AM Singapore time on that Saturday, the decision was still pending.
Ning ·5:34
How to verify: Check the FDA's public calendar for PDUFA dates and Summit Therapeutics' SEC filings or press releases for updates on the decision status. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
Primary sourceThe European Medicines Agency's CHMP backed Hansoh's aumolertinib and Innovent's sintilimab for lung cancer.
Ning ·6:53
How to verify: Check the EMA's CHMP assessment reports or Hansoh and Innovent's press releases regarding the positive opinion. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
LabCorp has run a Shanghai central lab since 2007 and a Singapore central lab since 2000, serving 14 Asia Pacific markets.
Basil Lui ·10:16
How to verify: Check LabCorp's corporate website or investor presentations for details on its laboratory infrastructure and global reach. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the 107 drug count and Class 1 innovative drug classification in the official 2026 National Reimbursement Drug List published by China's National Healthcare Security Administration.
- Check JW Therapeutics' pricing and reimbursement status for relma-cel in China's basic medical insurance fund.
- Confirm Novo Nordisk's nohoje reimbursement status in China and compare with global approval timelines.
- Review Summit Therapeutics' SEC filings for updates on ivonescimab's FDA PDUFA date and commercial leadership changes.
- Examine the European Medicines Agency's CHMP assessment reports for Hansoh's aumolertinib and Innovent's sintilimab.
- Investigate US regulations on exporting human genetic data and their impact on clinical trial infrastructure in Asia.
- Look for public evidence or lack thereof regarding Chinese samples being processed in Singapore labs as claimed by LabCorp.
- Assess the legal history of aumolertinib's approval and revocation involving AstraZeneca to understand regulatory risks.
Full transcriptexpand
- 0:04
- Basil Lui: Yesterday, China added 107 drugs to its national insurance list, including its first car tea, once priced above a million yuan. Who wins when Beijing writes the list?
- 0:19
- Unidentified speaker (UNKNOWN): I'm
- 0:19
- Basil Lui: Basso Lui, investing globally from Singapore with an Asia angle. This is the East West Bio Bridge. Brief, Biotech and Beyond for Sunday, November 15.
- 0:32
- Unidentified speaker (UNKNOWN): And
- 0:32
- Ning: I'm Ning, Basil's AI co host. Both our voices are AI clones. But Basil is the real person behind this show. Personal views, not investment advice.
- 0:47
- Unidentified speaker (UNKNOWN): On
- 0:47
- Ning: Saturday, in Suzhou, China's national Healthcare Security Administration published its 2026 National Reimbursement Drug List. That's the list of medicines the state's basic medical insurance will help pay for. It added 107 drugs, and 51 of them are what
- 1:07
- Ning: China calls class 1 innovative drugs, meaning brand new medicines rather than copies. The administration calls that a record.
- 1:33
- Basil Lui: Infused back. The one that got in is a Realmer cell, sold as Kate VA by Var JD. JW Therapeutics in Chinese, Yao Ming Juno, for adults with certain lymphomas that have come back or stopped responding. China Daily says it was priced at 1.29 million yu per
- 1:53
- Basil Lui: dose and is the first car tea on the basic list.
- 1:57
- Ning: How it got there matters. Last year, China launched a second, separate list. for expensive new drugs paid for by commercial health insurers rather than the state fund. Realma Cell was on that list first, and this year it moved across to the basic one. The commercial list itself added 12 drugs and now
- 2:17
- Ning: has 28. Those include Kars Gen's Ka T for a solid tumor in Chinese, Kerji Yaoye, and Belief Biomads Biomeds Gene. Therapy for Haemophilia B in Chinese, Sin Yen Yiao. Hemophilia B is an inherited bleeding disorder, and a gene therapy like this one aims to give
- 2:37
- Ning: the body a working copy of the clotting factor gene it lacks.
- 2:41
- Basil Lui: One thing we don't know is the actual prices. Negotiated prices for most drugs aren't published, so be careful with any discount you see quoted.
- 2:51
- Ning: There's an obesity twist for our GLP1 threat too. GLP1 drugs copy a gut hormone that lowers blood sugar and appetite. Four GLP1 injections were newly added, including Innovins Mazdutide in Chinese,
- 3:08
- Ning: which It's hits two hormone receptors at once. But the paper reports all four are reimbursed only for diabetes, not for weight loss.
- 3:22
- Basil Lui: And here's the east west part I find most interesting. Novo Nordis' weekly shot that combines a long acting insulin with semaglutide sold in China as nohoje got onto the list for adults with type two 2 diabetes whose blood sugar isn't controlled. on insulin or a GLP1.
- 3:42
- Basil Lui: Novo says that makes China the first country anywhere to reimburse it. A Danish company's new weekly diabetes shot, and the first country to reimburse it is China.
- 3:53
- Ning: Same for Chinese originals. Bayokin's Aiza brand. In Chinese, Baili By Li Tian Heng, which is partnered with Bristol Meyer Squib, got in for nasopharyngeal cancer that has come back.
- 4:03
- Ning: after earlier treatments in its first year on sale. That's a cancer at the back of the nose that is far more common in southern China and Southeast Asia.
- 4:17
- Basil Lui: And Ivor Neskimap, Arqueso's lung cancer drug in Chinese Kang Feng Shungwu, was renewed. The paper quotes an arcase. Aqueso vice president saying it, and their other two in one antibody were renewed at their original prices.
- 4:33
- Ning: Compare that with Washington. The US price fight is about most favored nation pricing, which ties American prices to what other rich countries pay. Global data counts 27% fewer new brand launches in the European
- 4:50
- Unidentified speaker (UNKNOWN): Union.
- 4:51
- Ning: countries. Two planned US Medicare price models will reference over the 17 months after the policy began. So in markets, the US references, some companies may now hold launches back. In China, 424 drugs from outside the list applied
- 5:11
- Ning: this year. And the trade-off, as we read it, is a lower. price in exchange for volume.
- 5:17
- Basil Lui: Which means who wins isn't simple. Patients get excess, the state gets a price, companies get volume. Whether that volume pays back the discount is the question we'll keep asking in our obesity drug threat.
- 5:34
- Ning: Now to Ivonnez Chimab in America. The FDA's target date is Saturday, November 14th, Washington time. When we checked at 6 o'clock this morning, Singapore Time, 5 in the afternoon on Saturday in Washington, Summit Therapeutics' latest filing with the US Securities Regulator was
- 5:54
- Ning: still from November 4th, and RTT News still listed the outcome as pending. Saturday in Washington ends at 1 o'clock this afternoon. Singapore Time.
- 6:04
- Basil Lui: We covered decision day yesterday, so just two points. A target date is a goal the FDA commits to, not a legal deadline, and silence by itself tells you nothing about which way a decision will go. Summit has said it will put out a press release and hold a call after the FDA acts.
- 6:23
- Unidentified speaker (UNKNOWN): The
- 6:23
- Ning: second point. Fierce Pharma reported this week that Summit's chief commercial officer is no longer with the company, and that other commercial leaders have left. Summit told Fierce it has had no broad layoffs, and fewer than five people have left the commercial team in recent months.
- 6:41
- Basil Lui: Meanwhile, Europe moved. On Thursday, the European Medicines Agency's drug committee backed three brand new medicines, not counting copies, and two of them come from Chinese drug makers.
- 6:53
- Ning: The first is Almolertinip from Hanso Pharmaceutical. In Chinese, Hansan Chuyang. It's a daily pill for lung cancer with EGFR mutations, which blocks the faulty growth signal driving the tumor. And it has a
- 7:12
- Ning: strange history. The European Community Commission approved it in February, then revoked it in September.
- 7:20
- Basil Lui: The revocation followed a case AstraZeneca brought against the Commission at the EU's general court. The Commission acted before the court ruled. AstraZeneca makes Tegriso Tagriso, the market-leading market leading pill of the same type. Hanso says the Commission found its 2022
- 7:39
- Basil Lui: filing, referenced some Tagriso results that were still under data protection at the time, and it calls that a procedural issue, not one about safety or efficacy. Hanso and its European partner refiled, and the committee has now backed it again.
- 7:56
- Unidentified speaker (UNKNOWN): The
- 7:56
- Ning: second is Sintilimap Sintelimap from Innovent, which helps the immune system attack cancer. Here for a common type. of lung cancer with chemotherapy. Fierce reports, the FDA turned it down in 2022 over China-only data and an outdated comparison group. Europe's committee has now said yes. Both
- 8:15
- Ning: still need the European Commission's final sign-off.
- 8:19
- Basil Lui: That's uh who gets to sell what, where, threat. In Europe, data protection rules can work as a moat and encourage. incumbents are entitled to enforce them. And CynthiaMap raises a question, we'll come back to. What decides whether Eastern data counts in the West? I have no personal holding in any of the
- 8:39
- Basil Lui: companies mentioned today.
- 8:42
- Ning: Last, the border for blood. On Wednesday, China's National Health Commission published revised rules on what it calls. human genetic resources. They replaced a 2023 version.
- 8:55
- Basil Lui: Ning, what's covered?
- 8:58
- Ning: Cells, whole blood, tissue, and similar samples, plus genetic material taken from them. Urine, stool, serum, and plasma are excluded. Serum and plasma are the liquid part of blood once the cells are removed.
- 9:13
- Basil Lui: And covered samples can still leave China, but only with approval from the National Health Commission plus customs clearance. So it's a license, not a ban.
- 9:23
- Ning: Two catches. Even plasma still needs a customs permit for so-called special articles, and genetic data from any sample must be reported, with a copy kept before it goes to foreign parties. There's also a fast lane. faster approvals for work with Hong Kong and Macau
- 9:42
- Ning: institutions.
- 9:43
- Basil Lui: Now the American side, since April last year, a Justice Department rule has barred Americans from giving China access to US human biospecimens that could yield bulk genetic data. For genomic data, bulk starts above 100 people. And under the biosecure law, the White House biose Budget
- 10:03
- Basil Lui: Office's first full list of so-called biotechnology companies of concern is due on December 18th.
- 10:11
- Ning: So each superpower now fences its own patients samples off from the other.
- 10:16
- Basil Lui: That's one reason the big trial labs built inside China. LabCorp Lab Corp says it has run a Shanghai central lab since 2007.
- 10:27
- Basil Lui: And it says it's Singapore's central lab running since 2000, serves 14 Asia Pacific markets and supports more than 2,500 active studies worldwide. Those are its own figures.
- 10:41
- Ning: Our honest reading Singapore is a neutral option for the rest of Asia Pacific, not a way around China's rules or America's. We found no public evidence of Chinese patient samples going to Singapore labs today. This is our reading of the rules, not legal advice.
- 10:59
- Basil Lui: We'll keep tracking it in our AI drug race thread under the question: can the chain cross the border?
- 11:08
- Ning: So, back to the opening. Beijing renewed Ifonessima Ivonesimap and wrote 107 new drugs. into its list. Europe's Drug Committee backed two Chinese lung cancer drugs, and Washington, so far, has said nothing.
- 11:23
- Basil Lui: Tomorrow is our Monday weekly on where the patients come from. Whenever the FDA acts on Ivoneskimap, it goes straight into that conversation. If you find this brief useful, follow the East West Bio Brief. on Spotify or Apple Podcasts.
- 11:42
- Ning: And for the transcripts and sources, subscribe to our newsletter on LinkedIn, also called the East West Biobrief. It goes out every Monday with our weekly roundup. That's today's brief. The key sources are in the show notes. See you tomorrow.
More from The East-West Bio Brief
Daily, Sat 14 Nov: FDA decision day for ivonescimab, Akeso's lung cancer bispecific
Episode discussion: FDA decision day for Akeso's ivonescimab; BioNTech buys voucher; Intellia deadline set
Speakers’ claims: Basil Lui and AI co-host Ning discuss the November 14 FDA decision deadline for Akeso's ivonescimab, a PD1/VEGF bispecific licensed to Summit Therapeutics. They analyze the HARMONi trial results, noting progression-free survival benefits but missed statistical significance in overall survival, complicated by a trial population weighted 60% toward Asian patients. The episode contrasts Akeso's path with BioNTech's purchase of a priority review voucher and highlights Intellia's upcoming March 2027 deadline for its CRISPR therapy lonvo-z.
Daily, Thu 12 Nov: A Shanghai pill wins FDA approval, after China said yes first
Episode discussion: Abbisko's pimicotinib wins FDA approval; Akeso/Summit awaits ivonescimab decision; Windward Bio files US IPO
Speakers’ claims: The hosts discuss Abbisko's pimicotinib receiving FDA approval for tenosynovial giant cell tumor, noting the trial's significant Chinese patient inclusion under Project AUBIS. They highlight Merck KGaA's commercial rights and the milestone payment structure. The episode covers the upcoming November 14 FDA decision for Akeso and Summit's ivonescimab, focusing on the statistical significance of overall survival data. Additional topics include South Korea's new policy allowing travelers to import GLP-1 drugs, Windward Bio's US IPO filing, ImvivaBio's lupus CAR-T data, Shionogi's licensing deal in Singapore, and Neuralink's expanded PRIME 2 trial.